Molecular Photoacoustic Tomography with Colloidal Nanobeacons by Pan, Dipanjan et al.
Molecular Photoacoustic Tomography with Colloidal
Nanobeacons**
Dipanjan Pana,+, Manojit Pramanikb,+, Angana Senpana, Xinmai Yangb, Kwang H. Songb,
Mike J. Scotta, Huiying Zhanga, Patrick J. Gaffneyc, Samuel A. Wicklinea, Lihong V Wangb,
and Gregory M. Lanzaa
Dipanjan Pan: dipanjan@wustl.edu; Lihong V Wang: lhwang@biomed.wustl.edu
a C-TRAIN and Division of Cardiology, Washington University School of Medicine, 4320 Forest
Park Avenue, Saint Louis, MO 63108, Fax: (+1) 314 454 7490, (Nanobeacons)
b Department of Biomedical Engineering, Washington University in St. Louis, One Brookings
Drive, St. Louis, MO 63130, Fax: (+1) 314 935 7448, (Photoacoustics)
c Department of Surgery St Thomas’s Hospital, London, UK
Abstract
Vascularly constrained, “soft” colloidal gold nanobeacons (GNB) demonstrate for the first time
that GNBs can be characterized as exogenous photoacoustic contrast agents for targeted detection
of fibrin, a major biochemical feature of thrombus. Fibrin-targeted GNBs provide a more than
tenfold signal enhancement in photo acoustic tomography (PAT) in the NIR wavelength window,
indicating their potential for diagnostic imaging with PAT.
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Molecular imaging has emerged as an interdisciplinary area that shows promise in
understanding the components, processes, dynamics, and therapies of a disease at a
molecular level.[1–2] The unprecedented potential of nanoplatforms for early detection,
diagnosis, and personalized treatment of diseases, is being explored in every noninvasive
biomedical imaging modality.[3] Despite myriad advances in the past decade, developing
contrast agents with prerequisite features for these imaging modalities continues to remain a
challenge.
In the last decade photoacoustic tomography (PAT) has been of particular interest because
of its satisfactory spatial resolution and high soft tissue contrast.[4–9] PAT is a novel,
hybrid, and nonionizing imaging modality that combine the merits of both optical and
ultrasonic imaging methods. It is highly sensitive to the optical absorption of biological
tissue. In PAT, tissue is irradiated with a short-pulsed laser beam. Absorption of optical
energy causes thermoelastic expansion and radiates photoacoustic (PA) waves from within
the irradiated tissue. A wide-band ultrasonic transducer is employed to acquire the PA
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waves, which are then used to quantify the optical absorption distribution in the tissue. Since
optical absorption is sensitive to physiological parameters, such as the concentration and
oxygenation of hemoglobin, PAT has the potential to provide both functional and molecular
imaging in vivo. PAT has been used for imaging and quantifying the levels of
vascularization and oxygen saturation in tumors.[4–7] These features are associated with
angiogenesis and hypoxia accompanying malignant tumors.[10] A number of contrast agents
for PAT have been suggested recently,[5,11] but only a few were shown to have the
potential for targeted imaging. To achieve molecular PAT, a major and mostly
uninvestigated task is to develop nanometric molecular contrast agents. The prerequisite
features include improved properties, such as contrast enhancement, stability, and high
target specificity.
We have prepared a novel class of accessible and commercially amenable platform
technologies: colloidal gold nanobeacons (GNB) of a “soft” nature to target vascular
pathology such as thrombus (fibrin), the proximate cause of stroke, and myocardial
infarction. Our hypothesis is that GNB will act as an exogenous contrast agent and could be
used as a targeted molecular agent in PAT. In a typical synthesis, a commercially available
organo-soluble, octylthiol-coated gold nanoparticle (AuNPs, 2 w/v%, 2–4 nm) is suspended
in almond oil (20 vol%) and micro fluidized with phospholipid surfactants (2 vol%). The
surfactant mixture is comprised of phosphatidylcholine (lecithin-egg PC, 91 mole% of lipid
constitutents), cholesterol (8 mole%) and biotin-caproyl-PE (1 mole%). This synthesis
resulted in approximately 1200 biotins per nanoparticle for biotin-avidin interaction. A
control nanobeacon is prepared identically except for exclusion of the gold nanoparticles.
The GNB particles have a nominal hydrodynamic diameter of 154±10 nm. The
polydispersity and zeta potential were measured as 0.08±0.03 and −47±7 mV (Brookhaven
Instrument Co.), respectively. Gold content, determined by ICP-MS, was 1080 μg/g of the
20% colloid suspension. UV-Vis spectroscopy confirmed the absorbencies at ~520 nm and
in the near-infrared (NIR) window (~900 nm), which correspond to the presence of gold
nanobeacons. The particle size and zeta potential of these nanobeacons have varied less than
5% over more than 100 days when stored at 4°C under argon in sealed serum vials (see
supporting information). Nanocrystal platforms (<50 nm) for NIR contrast have been
reported,[5,11] but particles within this size range rapidly distribute beyond the vasculature
and into tissues where binding to non-target cells or simple matrix entrapment can lead to
nonspecific signal and increased background noise. For GNB, the tiny metallic gold
nanoparticles (2 to 4 nm) are incorporated within a larger, vascular-constrained colloidal
particle that is constrained to the circulation and intra-luminal accessible biomarkers.
Figure 2(a) shows the PA signals (λ = 764 nm) obtained from a tygon tube (I.D. 250 μm,
O.D. 500 μm) filled with GNB and whole rat blood. At this light excitation the peak-to-peak
PA signal amplitude obtained from GNB is ~2.64 V, compared to the ~0.17 V peak-to-peak
PA signal amplitude from rat blood. Figure 2(b) shows the PA spectrum (peak-to-peak PA
signal amplitude versus excitation light wavelength) of the GNB for an excitation
wavelength range of 740–820 nm. The PA spectrum of rat blood is also shown in the same
figure. Figure 2(c) plots the ratio of the peak-to-peak PA signal amplitude of GNB to that of
rat blood. The PA signal from the tygon tube filled with GNB is more than 15 times strong
than that from rat blood. Over the 740–820 nm window the PA signal from GNB is more
than ten times stronger. The NIR window is well known for providing deep tissue PA
imaging at the expense of blood contrast due to the weak blood absorption. The strong PA
signal from GNB in the NIR region indicates the potential for molecular PAT of this
platform.
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The concept of molecular PAT of fibrin, a critical component of intravascular thromboses,
was studied next in vitro. Using acellular fibrin clot phantoms, the biotinylated gold
nanobeacons and the control nanobeacons (i.e., containing no metal) were targeted to the
fibrin clots with classic avidin-biotin interactions using a well-characterized biotinylated
anti-human fibrin-specific monoclonal antibody (NIB5F3).[12] Figures 3(a) and 3(b) show
cross-sectional PAT images of a LDPE (low density polyethylene) tube (~1 cc volume, I. D.
~6 mm) filled with plasma clot (control) and plasma clot targeted with biotinylated GNB,
respectively, using a curved array PAT system.[13] An 800 nm wavelength laser was used
for the light source. Both images are shown in the same color bar in Figure 3. The control
clot treated with targeted nonmetallic nanoparticles has negligible contrast (Figure 3(a)),
whereas the targeted fibrin clot shows up in the PAT image (Figure 3(b)) with high contrast.
Figures 3(c) and 3(d) show cross-sectional PAT images, using a PA breast scanner system,
[14] of the same control and targeted plasma clot, respectively. For this system, a 532 nm
wavelength laser source was used. As expected, the targeted plasma clot is clearly visible
(Figure 3(d)) in the PAT image, whereas the control image does not show any plasma clot
(Figure 3(c)). We have analytically tested the clot phantoms targeted with three controls,
biotinylated-GNB (with gold), non-biotinylated-GNB (with gold) and biotinylated-control
nanobeacons (no gold) for total gold content analyses. The total gold content of the clots
targeted with biotinylated GNB, non-biotin GNB and biotinylated control nanobeacons (no
metal) as determined by ICP-MS, were found to be 47 μg/g, ND (not detected, < 0.02 μg/g)
and ND respectively. The in vitro images along with ICP-MS data of the targeted plasma
clots illustrate the concept of intravascular PAT with GNB.
Preliminary in vivo blood vessel imaging was performed non-invasively in a rat model. The
pharmacokinetics of GNB in blood vessel following intravenous (IV) injection (3 ml/kg)
was monitored from femoral vein as changes in the PA signal with time (Figure 4a). As
desirable for molecular imaging, the detection of GNB as a blood pool contrast agent
required a 3-fold higher dose IV than would routinely be required for targeted imaging. The
expected bi-exponential decay of the PAT signal in blood is similar to reports with other
nanoparticles.[1c] Figure 4(b) shows a representative digital photograph of a rat taken prior
to imaging with the axillary surface shaved. Figure 4(c) shows the maximum amplitude
projection (MAP)[15] photoacoustic image. The vasculature was imaged with high contrast
to noise ratio (CNR = 50) and high spatial resolution of ~500 μm. Photoacoustic images
were taken immediately after the GNB injection with an interval of 25–30 minutes. Figure
4(d) shows the photoacoustic MAP[15] image (CNR = 68) of the same area 156 minutes
after the injection (see supplementary section for details). Both figures 4(c) and 4(d) are
shown with the same colorbar. As evident from Figure 4(d), the signal amplitude of the
blood vessels was increased by up to ~60% (c and d) compared to that in the control blood
vessels, after GNB (0.075 ml) injection.
In summary, we have successfully demonstrated the potential for targeted molecular PAT of
GNB as exogenous contrast agents. The gold nanobeacons provide a more than tenfold
signal enhancement in PAT in the NIR wavelength window. The in vitro and preliminary in
vivo PAT images both in the NIR wavelength and in the visible wavelength substantiate our
hypothesis.
Experimental Section
Preparation of GNB
In a typical experimental procedure, gold nanoparticles (2–4 nm) in toluene (100 mg) are
suspended in almond oil (4 mL) and vigorously vortexed to homogeneity. The suspension
was filtered through a small bed of cotton. The solvent was evaporated under reduced
pressure at 45°C. The surfactant co-mixture included high purity egg yolk
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phosphatidylcholine (91 mole%, 377.4 mg), cholesterol (8 mole%, 16.9 mg), and
biotinylated-dipalmitoyl phosphatidylethanolamine (1 mole%, 5.8 mg). The surfactant co-
mixture is dissolved in chloroform, evaporated under reduced pressure, dried in a 40°C
vacuum oven overnight, and dispersed into water by probe sonication. This suspension is
combined with the gold nanoparticle-suspended almond oil mixture (20% v/v), distilled de-
ionized water (77.3% w/v), and glycerin (1.7%, w/v). The mixture is continuously processed
thereafter at 20,000 PSI for 4 minutes with an S110 Microfluidics emulsifier (Microfluidics)
at 4°C. The nanobeacons are dialyzed against water using a 20,000 Da MWCO cellulose
membrane for a prolonged period of time and then passed through a 0.45 μm Acrodisc
Syringe filter. To prevent bacterial growth the nanobeacons are stored under an argon
atmosphere typically at 4°C. DLS (Dav)/nm =154±06 nm; Zeta (ζ)/mV = −47±08 mV; AFM
(Hav)/nm =101±51 nm. (For details, see supporting information)
Photoacoustic Spectroscopy system:[16]
Spectroscopy of the GNB was obtained using this system. Light Source: tunable Ti:sapphire
laser (LT-2211A, LOTIS TII) pumped by a Q-switched Nd:YAG (LS-2137/2, LOTIS TII),
pulse width: <15 ns, Pulse Repetition Rate (PRR):10-Hz. The incident laser fluence on the
sample surface was controlled to conform to the American National Standards Institute
(ANSI) standards.[17] Transducer used: 5-MHz central frequency, spherically focused -
2.54 cm focus length, 1.91 cm diameter active area element, and 72% bandwidth (V308,
Panametrics-NDT). Amplifier: a low-noise amplifier (5072PR, Panametrics-NDT). Data
acquisition: digital oscilloscope (TDS 5054, Tektronix).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Preparation of gold nanobeacons: (i) Suspension of octylthiol-coated gold nanoparticle
(toluene) in vegetable oil (almond oil), vortex and mixing, filter using cotton bed,
evaporation of toluene under reduced pressure at 60°C, vortex; (ii) preparation of
phospholipid thin film (iii) resuspension of the thin film in water (0.2 uM), microfludization
at 4°C, 12,000 psi, dialysis (cellulosic membrane, MWCO 20K. (A) TEM image of gold
nanobeacons (drop deposited over nickel grid, 1% uranyl acetate; scale: 100 nm); (B) AFM
image of gold nanobeacons: Hav/nm =101±51 nm (C) UV-vis spectroscopic profile (not
normalized).
Pan et al. Page 6
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2010 June 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
(a) PA signals generated from a tygon tube (I.D. 250 μm, O.D. 500 μm) filled with GNB and
rat blood. The excitation light is of 764 nm wavelength. (b) PA spectrum of GNB and blood
over a 740–820 nm range of NIR wavelengths. (c) Ratio of the peak-to-peak PA signal
amplitudes generated from GNB to those of blood.
Pan et al. Page 7
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2010 June 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Cross-sectional PA image of a LDPE tube (~1cc volume, I.D. ~6 mm) filled with plasma
clot: (a) control, (b) targeted with GNB using a curved array PA system (λ = 800 nm). (c)
Control, (d) targeted with GNB using a photoacoustic breast scanner system (λ = 532 nm).
Optical images of plasma clots stained with Biebrich Scarlet-Acid Fuchsin Solution (e)
targeted with GNB and (f) control.
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Figure 4.
Non-invasive in vivo PA imaging (MAP)[15] of rat. For all PA images, the laser was tuned
to 766 nm wavelength. (a) Pharmakokinetics of GNB in blood vessel after injection. The PA
signal from the femoral -vein was monitored as intravenous injection (IV) was given with 3
ml/kg doses through tail vein. (b) Photograph of the rat after the hair was removed from the
scanning region before taking the PA images. The scanning region is marked with a black
dotted square. (c) Control PA image acquired before GNB injection. Bright parts represent
optical absorption, here, from blood vessels. (d) PA image (MAP) acquired after 156
minutes of GNB injection (e) Optical photograph of the rat with the skin removed after PA
imaging.
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